REPL Replimune
- 8.365
- -1.095-11.58%
- 8.370
- +0.005+0.06%
Replimune News
Express News | Replimune Shares Are Trading Higher After the Company Announced a Private Placement Financing With an Institutional Investor for Gross Proceeds of Approximately $100 Million
Express News | Replimune Announces Private Placement Financing With An Institutional Investor For Gross Proceeds Of ~$100M
Express News | Replimune Group Inc: Proceeds Enable Full Commercial Scale up to Support a Potential Launch in 2H 2025
Express News | Replimune Announces $100 Million Private Placement Financing
Replimune(REPL.US) Officer Sells US$119.11K in Common Stock
$Replimune(REPL.US)$ Officer Xynos Konstantinos sold 15,881 shares of common stock on Jun 7, 2024 at an average price of $7.5 for a total value of $119.11K.Source: Announcement What is statement of ch
Express News | Replimune Group Inc : JP Morgan Cuts Target Price to $17 From $19
Form 144 | Replimune(REPL.US) Officer Proposes to Sell 119.19K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Replimune(REPL.US)$ Officer Konstantinos Xynos intends to sell 15,881 shares of its common stock on Jun 7, with a total market value of approximately $119.19K. Sourc
Replimune Group Is Maintained at Overweight by Barclays
Replimune Group Is Maintained at Overweight by Barclays
Replimune (REPL) Gains on Positive Data From Melanoma Study
Barclays Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $17
Barclays analyst Peter Lawson maintains $Replimune(REPL.US)$ with a buy rating, and adjusts the target price from $13 to $17.According to TipRanks data, the analyst has a success rate of 41.8% and a t
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday.Shares of Vail Resorts, Inc. (NYSE:MTN) fell sharply in today's pre-market trading after the co
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced
Replimune Group Is Maintained at Buy by HC Wainwright & Co.
Replimune Group Is Maintained at Buy by HC Wainwright & Co.
Replimune Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/07/2024 139.44% HC Wainwright & Co. $12 → $17 Maintains Buy 12/06/2023 83.1% Barclays $50 → $13 Maintai
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $17
H.C. Wainwright analyst Robert Burns maintains $Replimune(REPL.US)$ with a buy rating, and adjusts the target price from $12 to $17.According to TipRanks data, the analyst has a success rate of 24.0%
Express News | Replimune Group, Inc. : H.c. Wainwright Raises Target Price to $17 From $12
Sector Update: Health Care
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%. The iShares Biotechnology ETF (IBB) eased 0.2%. In
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results.G-III Apparel Group posted adjusted earn
Replimune Announces Positive Results From The Primary Analysis Of RP1, Nivolumab; Stock Up
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersVirax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37%
Analysis
Price Target
No Data
